The Special Report, "Clinical Pathways to Address the Challenges of Treatment Resistance and Relapse in Multiple Myeloma," reviews the challenges associated with different phases of treatment for multiple myeloma and how clinical pathways can support physicians’ decision-making. READ MORE

Author Insights

Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.

READ MORE

Research in Review

The Levine Cancer Institute of the Carolinas HealthCare System has had a large impact on hematopoietic cell transplant outcomes.

READ MORE

Resources

The National Comprehensive Cancer Network has implemented categories of preference for recommendations within their clinical practice guidelines in oncology.

READ MORE

Special Reports

The Special Report, "Clinical Pathways to Address the Challenges of Treatment Resistance and Relapse in Multiple Myeloma," reviews the challenges associated with different phases of treatment for multiple myeloma and how clinical pathways can support physicians’ decision-making.

READ MORE

The Special Report, "Clinical Pathways to Address the Challenges of Treatment Resistance and Relapse in Multiple Myeloma," reviews the challenges associated with different phases of treatment for multiple myeloma and how clinical pathways can support physicians’ decision-making.

READ MORE

The final section of the special report speculates on the future treatment landscape for relapsed or refractory multiple myeloma.

READ MORE

The fourth section of the report reviews the economic implications of a multiple myeloma diagnosis.

READ MORE